Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
Fernández-Fernández, Beatriz (Red de Investigación Renal (REDINREN))
D'Marco, Luis (Hospital Clínic Universitari (València))
Górriz, Jose Luis (Universitat de València)
Jacobs-Cachá, Conxita (Hospital Universitari Vall d'Hebron)
Kanbay, Mehmet (Koc University School of Medicine)
Luis-Lima, Sergio (Red de Investigación Renal (REDINREN))
Porrini, Esteban (University of La Laguna)
Sarafidis, Pantelis (Hippokration Hospital)
Soler, María José (Hospital Universitari Vall d'Hebron)
Ortiz, Alberto (Red de Investigación Renal (REDINREN))
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Hospital admissions and mortality from the Coronavirus disease 2019 (COVID-19) pandemic are spreading throughout the world, and second and third waves are thought to be likely. Risk factors for severe COVID-19 include diabetes, chronic kidney disease and cardiovascular disease. Currently, there is no vaccine and no approved therapy. Therapeutic approaches are aimed at preventing viral replication and spread, limiting the impact of the inflammatory overdrive (cytokine storm), preventing thromboembolic complications and replacing or supporting organ function. However, despite organ support, mortality is currently 65% for those receiving advanced respiratory support and 78% for those requiring renal replacement therapies. Thus, efforts should be made to provide adjuvant organ protection therapy. This may imply novel therapies in clinical development (e. g. , the Fas ligand trap asunercept), but uptake of repurposed drugs already in clinical use may be faster. In this regard, sodium glucose co-transporter-2 (SGLT2) inhibitors were recently shown to protect the heart and kidney both within and outside of a diabetic milieu context. Further, preclinical data support a beneficial effect for the lung. We now discuss the potential benefits and risks of SGLT2 inhibitors in COVID-19 and an ongoing clinical trial testing the impact of dapagliflozin on outcomes in COVID-19 patients with respiratory failure.
Ajuts:	Instituto de Salud Carlos III PI17/00257 Instituto de Salud Carlos III PI18/01386 Instituto de Salud Carlos III PI19/00588 Instituto de Salud Carlos III PI19/00815 Instituto de Salud Carlos III DTS18/00032 Instituto de Salud Carlos III AC18/00064 Instituto de Salud Carlos III AC18/00071 Instituto de Salud Carlos III RD016/0009
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	COVID-19 ; Diabetes ; Chronic kidney disease ; Cardiovascular ; SGLT2 ; Canagliflozin ; Dapagliflozin ; Empagliflozin
Publicat a:	Journal of clinical medicine, Vol. 9 (june 2020) , ISSN 2077-0383

DOI: 10.3390/jcm9072030
PMID: 32605278

16 p, 1.1 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats